Experimental Compound TOFA Boosts Fat Burning by 18% in Mice, Offers New Hope Against Obesity

Introduction

In a significant development for metabolic research, scientists at the University of California - Berkeley have identified an experimental compound that could revolutionize the treatment of obesity and related metabolic disorders. The compound, known as 5-tetradecyloxy-2-furoic acid (TOFA), has demonstrated a remarkable ability in mice to increase the body's energy expenditure and promote fat loss, crucially without the detrimental loss of muscle mass often associated with weight reduction efforts. This innovative approach targets the energy-spending side of the metabolic equation, offering a potential alternative or complement to current appetite-suppressing therapies.

Key Details

• Compound: 5-tetradecyloxy-2-furoic acid (TOFA), an ACC inhibitor.
• Mechanism: TOFA interferes with lipid production while activating genes that encourage cells to burn fat for fuel, increasing energy expenditure.
• Observed Effects in Mice: Increased energy use by up to 18%, reduced body fat without significant muscle loss, improved insulin sensitivity, better glucose control, reduced triglyceride levels, and ameliorated signs of fatty liver disease.
• Combination Therapy: TOFA showed synergistic effects when combined with GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), enhancing weight loss and metabolic improvements beyond either treatment alone.
• Publication: The findings were published on August 21, 2026, in the journal Science Advances.
• Lead Researchers: Anders Näär (UC Berkeley) and Justin Y. Lee (UCSF/UC Berkeley).
• Funding: Supported by UC Berkeley discretionary funds, UCSF Liver Center, and University of Michigan Animal Phenotyping Core.

Background

The landscape of obesity treatment has been dramatically reshaped by the advent of GLP-1 receptor agonists. Medications such as Ozempic, Wegovy, Mounjaro, and Zepbound have achieved considerable success in facilitating weight loss and managing conditions like type 2 diabetes and non-alcoholic fatty liver disease. However, these drugs primarily function by suppressing appetite, which, while effective for weight reduction, can lead to undesirable side effects including gastrointestinal distress, potential nutritional deficiencies, and, notably, a loss of lean muscle mass. This muscle loss is a significant concern, as it can contribute to frailty and negatively impact long-term metabolic health.

Recognizing these limitations, researchers at UC Berkeley embarked on a quest for a different therapeutic strategy. Their focus shifted from reducing calorie intake to increasing calorie expenditure. This involves boosting the body's metabolic rate, encouraging it to burn more energy naturally. TOFA, a compound initially synthesized in the 1970s, emerged as a promising candidate. It belongs to a class of drugs known as ACC (acetyl-CoA carboxylase) inhibitors, which are designed to curb the body's production of lipids like cholesterol and triglycerides. While some ACC inhibitors have shown potential, they have faced hurdles in clinical development, partly due to their tendency to elevate triglyceride levels, a risk factor for cardiovascular disease.

Impact Analysis

The UC Berkeley study highlights TOFA's unique multifaceted action. Unlike other ACC inhibitors, TOFA not only inhibits lipid synthesis but also activates specific cellular receptors, PPARα and PPARδ. These receptors play a crucial role in fat metabolism, signaling cells to take up and burn fatty acids for energy. This dual action appears to be key to its effectiveness. In the mouse models, TOFA triggered an increase in energy expenditure of up to 18% without altering physical activity levels or body temperature, suggesting a direct impact on metabolic efficiency. Crucially, it achieved this fat reduction without the significant muscle wasting observed with other approaches.

“Body weight responds to two levers: taking in fewer calories, or spending more energy,” said Anders Näär, a professor of metabolic biology and nutrition at UC Berkeley and senior author of the study. “GLP-1s work almost entirely on the first, so we went after the second.”

Furthermore, TOFA's ability to avoid elevating triglyceride levels, a common drawback of other ACC inhibitors, makes it a potentially safer option. The study also demonstrated that TOFA's combined inhibitory and activating effects were more potent than using separate compounds designed for each function. Perhaps most excitingly, when TOFA was administered alongside established GLP-1 medications, the results were significantly amplified. This synergistic effect suggests that TOFA could serve as a powerful complementary therapy, enhancing the benefits of current obesity treatments while potentially mitigating some of their drawbacks, such as muscle loss.

Broader Context

The pursuit of novel obesity treatments is a critical global health endeavor, given the escalating rates of obesity and its associated comorbidities, including type 2 diabetes, cardiovascular disease, and certain cancers. While GLP-1 agonists represent a major therapeutic advance, their cost, side effect profile, and the potential for muscle loss necessitate the exploration of alternative and complementary strategies. TOFA's mechanism—boosting energy expenditure—addresses a fundamental aspect of energy balance that has been less directly targeted by pharmacological interventions. Its potential to work alongside existing therapies also aligns with a growing trend towards personalized and combination treatment approaches in chronic disease management.

Future Outlook

The promising results observed in mice provide a strong rationale for advancing TOFA research towards human clinical trials. The researchers have taken a proactive step by establishing a company, ReRx Therapeutics, with support from UC Berkeley's entrepreneurial ecosystem, to facilitate this transition. Future studies will need to rigorously assess TOFA's safety, tolerability, and efficacy in human subjects. If successful, TOFA could offer a new oral medication option for weight management and metabolic health improvement, either as a standalone treatment or in combination with GLP-1 drugs. This could provide a much-needed therapeutic avenue for individuals who do not respond optimally to current treatments or who experience significant side effects.

Conclusion

The investigation into TOFA by UC Berkeley scientists represents a significant stride in the fight against obesity and metabolic dysfunction. By targeting energy expenditure—a less explored pathway compared to appetite suppression—TOFA shows potential to induce fat loss without compromising muscle mass. Its favorable metabolic profile in mice and its synergistic effects with GLP-1 drugs position it as a highly promising candidate for future therapeutic development. While human trials are essential to confirm these findings, TOFA offers a beacon of hope for more effective and potentially safer strategies to combat the global obesity epidemic.